Crystalline forms of zuclomiphene citrate
The present invention provides novel crystalline forms of zuclomiphene citrate. Specific crystalline forms provided by the present invention include zuclomiphene citrate Forms APO-I, APO-II, APO-III, and APO-IV. Also provided are pharmaceutical compositions including the zuclomiphene citrate crystalline forms, processes for the preparation thereof and the use of these forms in the treatment of a disorder selected from the group including osteoporosis, bone fractures, loss of bone mineral density (BMD) and hot flashes in a subject suffering therefrom.
1. A crystalline form of zuclomiphene citrate, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 2θ (±0.2°), at 8.8°, 9.6° and 11.7°.
2. The crystalline form of claim 1 , further comprising at least three peaks, expressed in degrees 2θ (±0.2°), selected from the group consisting of: 10.9°, 12.4°, 14.7°, 14.9°, 17.3°, 17.8°, 18.6°, 19.9°, 20.5°, 23.6° and 25.4°.
3. The crystalline form of claim 1 , characterized by a DSC thermogram comprising an endothermic peak with a peak onset at about 140° C. and a peak maximum at about 142° C.
4. A crystalline form of zuclomiphene citrate, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 2θ (±0.2°), at 8.3°, 8.7° and 15.2°.
5. The crystalline form of claim 4 , further comprising at least three peaks, expressed in degrees 2θ (±0.2°), selected from the group consisting of: 9.7°, 11.1°, 11.6°, 12.1°, 16.8°, 17.6°, 20.4° and 23.6°.
6. The crystalline form of claim 4 , characterized by a DSC thermogram comprising an endothermic peak with a peak onset at about 138° C. and a peak maximum at about 140° C.
7. A crystalline form of zuclomiphene citrate, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 2θ (±0.2°), at 8.7°, 9.8° and 10.5°.
8. The crystalline form of claim 7 , further comprising at least three peaks, expressed in degrees 2θ (±0.2°), selected from the group consisting of: 11.6°, 12.3°, 15.3°, 16.9°, 18.0°, 18.6°, 19.4°, 20.4°, 21.0° and 24.5°.
9. The crystalline form of claim 7 , further comprising peaks in the PXRD diffractogram, expressed in degrees 2θ (±0.2°), at 11.6°, 12.3°, 15.3°, 16.9°, 18.0°, 18.6°, 19.4°, 20.4°, 21.0° and 24.5°.
10. The crystalline form of claim 7 , characterized by a DSC thermogram comprising an endothermic peak with a peak onset at about 140° C. and a peak maximum at about 143° C.
11. A crystalline form of zuclomiphene citrate, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 2θ (±0.2°), at 8.5°, 10.3° and 13.8°.
12. The crystalline form of claim 11 , further comprising at least three peaks, expressed in degrees 2θ (±0.2°), selected from the group consisting of: 9.5°, 11.3°, 12.5°, 13.1°, 14.4°, 15.5°, 17.1°, 18.1°, 18.8° and 19.7°.
13. The crystalline form of claim 11 , further comprising peaks in the PXRD diffractogram, expressed in degrees 2θ (±0.2°), at 9.5°, 11.3°, 12.5°, 13.1°, 14.4°, 15.5°, 17.1°, 18.1°, 18.8° and 19.7°.
14. The crystalline form of claim 11 , providing a PXRD diffractogram comprising peaks in substantially the same positions (±0.2° 2θ) as those shown in FIG. 4 .
15. The crystalline form of claim 11 , characterized by a DSC thermogram comprising an endothermic peak with a peak onset at about 144° C. and a peak maximum at about 146° C.
16. The crystalline form of claim 15 , characterized by a DSC thermogram that is substantially the same in appearance as the DSC thermogram provided in FIG. 8 .
17. A pharmaceutical composition comprising the crystalline form of zuclomiphene citrate of claim 11 , and one or more pharmaceutically acceptable excipients.
18. The pharmaceutical composition of claim 17 , wherein the pharmaceutical composition is a capsule or a tablet.
19. A process for the preparation of the crystalline form of zuclomiphene citrate of claim 11 , the process comprising, combining zuclomiphene free base and citric acid in a solvent and crystallizing the zuclomiphene citrate using a condition selected from the group consisting of:
(1) combining the zuclomiphene free base and citric acid at a controlled rate;
(2) combining the zuclomiphene free base and citric acid at an elevated temperature; and
(3) maintaining the zuclomiphene citrate for a period of time.
20. The process of claim 19 , wherein the solvent is an alkyl ester.
21. The process of claim 20 , wherein the process comprises condition (1), (2), and (3).
22. The process of claim 19 , wherein the elevated temperature is a temperature in the range of about 50° C. to about 70° C.
23. The process of claim 19 , wherein the period of time is in the range of about 16 hours to about 48 hours.